SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 2185270

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 2185270

Trivalent Inactivated Influenza Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

PUBLISHED:
PAGES: 150 - page report
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 4850
PDF, Excel & 1 Year Online Access (2-5 User License)
USD 6700
PDF, Excel & 1 Year Online Access (Corporate License)
USD 8850
PDF, Excel & 1 Year Online Access (Global License)
USD 10000

Add to Cart

Trivalent Inactivated Influenza Vaccine Market

The future of the global trivalent inactivated influenza vaccine market looks promising with opportunities in the hospital, clinic, and public health agency markets. The global trivalent inactivated influenza vaccine market is expected to reach an estimated $8.5 billion by 2035 from $4.7 billion in 2027 with a CAGR of 9.1% from 2027 to 2035. The major drivers for this market are growing awareness about the importance of flu prevention, rising seasonal influenza outbreaks, and increased government vaccination initiatives.

  • Lucintel forecasts that, within the type category, intramuscular injection is expected to witness the highest growth over the forecast period due to most widely used and recommended method for administering flu vaccines.
  • Within the application category, public health agency is expected to witness the highest growth due to they play a central role in large-scale vaccination campaigns.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to high healthcare access, and strong public health initiatives.

Emerging Trends in Trivalent Inactivated Influenza Vaccine Market

Trivalent Inactivated Influenza Vaccine (TIV) will transition from volume-based, seasonal supply to differentiated protection, and flexible manufacturing during the period of 2025-2027. WHO strain recommendations, aging populations, and increased procurement scrutiny will impact product choices. Lucintel believes competition will shift to platform economics, clinical evidence, and reliable supply rather than simply the number of doses.

  • Cell-based Production: WHO's February 2025 recommendation maintained three influenza components, creating the need for manufacturing platforms that address the egg adaptation issue. For the next three to five years, cell-based capacity will drive supply and potentially influence contract awards.
  • Higher-value Formulations: The growing higher risk population of severe influenza cases, specifically the older adult population, will create interest in high-dose and adjuvanted TIVs. Continued evidence of better immune response and premium pricing will drive the growth of value from volume sales.
  • Needle-free Delivery: Intranasal and microneedle delivery systems are moving from research to operational delivery systems while 2025 initiatives continue accessibility from community pharmacy and health post delivery. Ease of use, especially with adults and children, will expand demand.
  • Manufacturing Automation: The periods of peak demand will create opportunity for Facilities to increase capacity with quality systems and automated inspection. Automation will create a competitive advantage especially as pricing is expected to decrease.
  • Regional Supply Resilience: After disruptions from the pandemic, governments and public procurement clients are looking more toward domestic or diversified vaccine capacity. In 2025, preparedness funding was still a concern for the European and North American regions. For supply tenders, there will be increased preference for regional production and dual sourcing, as well as an acceptance of an increased risk of delays of cross-border supply.

For the period of 2025 to 2027, trivalent inactivated influenza vaccine demand will select suppliers with consistent capacity while offering differentiated protection. Suppliers cannot rely on updates of influenza strains in order to grow. There is clear preference for cell-based production, higher-value formulations, and simpler administration along with regional resilience. Manufacturers who are able to offer better value while controlling prices will gain long-term market position in both public and private sectors.

Recent Developments in the Trivalent Inactivated Influenza Vaccine Market

The trivalent inactivated influenza vaccine market is in a reset phase as manufacturers switch from quadrivalent to trivalent. Volunteer activity is most evident in regulatory, planning, and procurement activity for 2025-2027. Lucintel expects that in the future, demand growth will be less important than supply shaping, especially for markets where seasonal demand is dependent on publicly funded vaccinations.

  • WHO Strain-selection Decision: In February 2025, WHO suggested that for the 2025-2026 flu season, Member States should not produce vaccines containing the B/Yamagata lineage. Since March 2020, this strain of the flu has not been detected around the world. This continues the standardization of all influenza vaccines as trivalent.
  • US Regulatory Conversion: In February 2025, the FDA supported, on a non-compliance basis, the use of trivalent vaccines in the 2025-2026 flu season. This required all manufacturers to make formulation and labeling changes. The impact is simplification of the flu vaccine market in the US, but it also creates a concentrated replacement of doses, packaging, and clinical supplies after a relatively long production hiatus.
  • Sanofi: Sanofi's change produces trivalent versions of Fluzone, replacing the quadrivalent versions in all major markets for the 2025 season. Sanofi's market position will encourage further customer changes and tighter supply for the rival companies, who have to maintain supply to pharmacy and public sector segments.
  • GSK: GSK also moved FluLaval into trivalent for the 2025-2026 season following regulatory changes for the 2025 season. This increases competition for approved trivalent vaccines and gives health systems at least two large multinational suppliers during the transition period.
  • Manufacturing-network Adaptation: CSL Seqirus is already producing trivalent influenza vaccines for the 2025-2026 campaign, comprising cell-based and egg-based products. The shift will affect procurement in the coming 3 to 5 years. Buyers are starting to evaluate platform flexibility and supply resilience together with price.

In the short-term, market growth will be primarily from replacing old quadrivalent vaccines rather than introducing new antigens. Suppliers with validated capacity, dependable strain updates, and broad contracting should see growth. While demand will remain seasonal, regulatory changes have lessened the uncertainty in the market. Manufacturers who succeed in the conversion will gain superior supply positions in public procurement and retail channels.

Strategic Growth Opportunities in the Trivalent Inactivated Influenza Vaccine Market

The trivalent inactivated influenza vaccine market will be economically viable over the next few years, thanks to demand fluctuations caused by changing baseline strain-selection, population dynamics, procurement clemency, and progressive adult vaccination policies from 2024 to 2026. Lucintel's market framing shows that after satisfying pediatric pen supply, revenue will shift toward advanced protection, local production, and service-based contract fulfillment.

  • Protection of The Older Adults: Stronger pricing should be possible with high-dose and adjuvanted trivalent vaccines in comparison with standard vaccines, where less potent immune responses are generated. The WHO endorsed the vaccine strain selection for the 2025-2026 Northern Hemisphere, and with increasing numbers of older adults and rising hospitalization costs, should encourage reimbursement of higher pricing over the next 3 to 5 years.
  • Employer Vaccination Programs: Vaccines can be sold directly to institutions (via occupational health) with the goal of avoiding the reliance on government contracts. Seasonal influenza vaccination was recommended for all persons 6 months and older in 2025 public health guidance issued by the U.S. In the upcoming years, corporate purchasing should remain economically viable due to employee absences.
  • Economic Growth: Regional fill-finish and technology transfer partnerships may improve tendering opportunities and decrease exposure to the cold chain. Influenza, a majority of the supply, is concentrated among a limited number of manufacturers, as reported by the WHO in May 2025. Local capacity in the AP, LA, and African regions will influence purchasing decisions.
  • Private Retail Channels: Pharmacies and primary care networks provide vaccination services outside of mass public campaigns. The U.S. CDC reported in September 2025 that influenza vaccines continued to be available at pharmacies and clinics across the country. Offering vaccination services at retail locations will encourage higher and more predictable demand from adults.
  • Outcome-based Supply Services: Manufacturers can integrate forecasting, inventory management, and reporting of vaccinations with sales of the product. In March 2025, WHO published updated influenza surveillance recommendations which outlined three recommended components of the influenza virus. Improved data allows purchasers to limit waste and select suppliers who offer specific vaccine performance.

The next five years will distinguish the leaders from the rest. It will take reliable supply, clinical value, and a creative partnership approach to capture both established and developing market demand. Opportunities to price higher and capture a greater volume will exist in private sector contracts, employer-based contracts, older adult contracts, and vaccination campaigns focused on unvaccinated regions, when compared to the public contracts. Manufacturers who fill and finish locally and document outcomes from those services will retain and grow their share of the seasonal market.

Trivalent Inactivated Influenza Vaccine Market Drivers and Challenges

Factors driving growth of the trivalent inactivated influenza vaccine market include technology, burden of illness due to seasonal disease occurrence, healthcare economics, public health policies and manufacturing capacity. Market demand is sustained by the growing population of older persons, coupled with improved surveillance systems for timely assessment of strain types for vaccines. Market demand is also sustained by improved surveillance. Regulatory, procurement and vaccination policies will also affect market demand for the vaccine. Lucintel report indicates that, more than ever before, market competitors are winning with innovation and market readiness. However, complexities in production, unpredictable seasonal demand, low margins, and unmet target populations, etc., will negatively impact the ability to grow the market in the coming years.

The factors responsible for driving this market include:

  • Increasing Seasonal Burden: For the foreseeable future, influenza will continue to place a burden on our health systems, particularly on the young and old, pregnant women and the immune compromised. During 2025-2026, the three vaccine viruses recommended by the World Health Organization for the northern hemisphere (February 2025 production) reinforce the need for trivalent vaccines. The risks of hospitalization and complications of influenza will drive governments, employers and healthcare systems to support regular vaccinations. The next three to five years will experience regular seasonal outbreaks in combination with newly established vaccination program for adults. Vaccination coverage will depend on confidence, severity of the outbreak, timing and the level of trust in the healthcare system.
  • Regulatory and Public-Health Support: The establishment of national immunization policies and recommendations from public health organizations provides a foundation for market growth. Evidence suggests that the European Union supports strategies for seasonal influenza and promoting vaccination of high-risk populations. Also, many countries continue to fund vaccination of older adults and health care workers. In 2025, several jurisdictions continued implementing age-based campaigns directed at adults older than 65 years. In the next three to five years, it is anticipated that more robust planning, wider reimbursements, and routine vaccinations incorporated into primary care will reduce demand volatility and improve market access.
  • Manufacturing and Technology Advancement: Improvements in egg-based process control, cell-culture production, quality testing, and digital surveillance have allowed manufacturers to better respond to evolving influenza strains. The recommendation for the 2025 Southern Hemisphere vaccine included three components, illustrating the continued need for harmonization of strain selection and formulation (September 2024). Newer analytical tools will enable vaccine manufacturers to better forecast demand, utilize their facilities more effectively, and improve product yields while also reducing product failure rates. Over the next three to five years, improvement in process control and increased characterization will improve product quality and reliability of supply while allowing manufacturers to better manage reduced timelines for preparation for the influenza season.
  • Growing Preference for Seasonal Prevention: Increasing awareness of influenza's contribution to work absences, overburdened hospitals, and worsening family health is leading more people to get preventative vaccinations beyond high-risk groups. In the U.S., thousands of vaccinations were administered by pharmacies across the country during the 2024-2025 flu season. This is due to the growing role of pharmacies in vaccine delivery. In the coming years, it will be even easier to get vaccines, and public health outreach will reach more people, including adults, caregivers, and high-risk populations who currently underserve the market.
  • Infrastructure and Distribution Expansion: Infrastructure for vaccine distribution combined with cold-storage logistics and electronic registries, plus the deployment of mobile clinics and pharmacies, improves access to seasonal vaccinations. Influenza, the World Health Organization's influenza vaccine, is formulated twice a year, and therefore requires supply to be planned well in advance (February 2025). Better coordination and forecasting of demand will help distribute vaccines based on anticipated need while limiting wasted doses in areas with lower demand. Over the next three to five years, integrated vaccine delivery systems and flexible vaccination sites will lead to greater demand fulfillment and help align vaccine production to local epidemiological needs.

The challenges facing this market include:

  • Demand Uncertainty and Waste: Different severity levels of flu across geographic locations and unpredictable flu strains coupled with uncertainty surrounding public behavior results in unpredictable or difficult to forecast demand. Vaccines are produced several months before the seasonal peak of flu cases. Because vaccines have an expiration date and unused vaccines are wasted, there are potentially millions of unused flu vaccines each season. Vaccine demand is inherently unpredictable and will continue to pose challenging inventory management issues for manufacturers for the next 3 to 5 years. Coordination will also be needed to mitigate the risks of over-production or stockouts, including flexibility of manufacturing and distribution.
  • Complexity of Manufacturing and Supply: The production of trivalent vaccines is further complicated by the need for flexibility and quality control, as well as timely access to eggs, cellular substrates, components, and staff. A single production disruption can create a lengthy delay in the supply of vaccines during a short timeframe. Each year the WHO recommends three vaccines for each of the three components, which results in a need to adjust the manufacturing plan. Supply disruptions, demand volatility and timely regulatory reviews pose further challenges and constraints to supply over the next 3 to 5 years.
  • Pricing Pressure and Unequal Access: Funded by the government, large-scale programs can be subject to budgetary constraints leading to narrower margins. Barriers such as public tenders and limits on reimbursements, competitors in the supply market, budget constraints, limitations in financing among low-income countries, insufficient cold-chain infrastructure, lack of health care workers and other barriers, are likely to impact programs, offering influenza vaccinations. Over the next three to five years, there will be a considerable disparity in the affordability and distribution of the vaccine. However, with the continued need for the vaccine, tiered pricing, pooled procurement, and pharmacy-led delivery will improve access while preserving commercial sustainability.

The annual recurring disease burden, combined with available public health support, establishes a growing market for trivalent inactivated influenza vaccines. Manufacturing, delivery channels, and prevention awareness improve as barriers to market growth in some regions are sustained with unequal access, pricing pressure, and seasonal uncertainty. The manufacturing process is complex and has uncertain markets. The next three to five years will establish competitive advantage to those manufacturers who are able to combine reliable quality at flexible capacity with the broadest distribution. Overall, the market is poised for steady growth, with the potential to reach more of the unserved and underserved markets.

List of Trivalent Inactivated Influenza Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies trivalent inactivated influenza vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the trivalent inactivated influenza vaccine market companies profiled in this report include-

  • AstraZeneca
  • Sanofi S.A
  • Abbott
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer

Trivalent Inactivated Influenza Vaccine Market by Segment

The study includes a forecast for the global trivalent inactivated influenza vaccine market by type, application, and region.

Trivalent Inactivated Influenza Vaccine Market by Type [Value ($B) from 2019 to 2035]:

  • Nasal Spray
  • Intramuscular Injection
  • Intradermal Injection

Trivalent Inactivated Influenza Vaccine Market by Application [Value ($B) from 2019 to 2035]:

  • Hospital
  • Clinic
  • Public Health Agency
  • Others

Trivalent Inactivated Influenza Vaccine Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Trivalent Inactivated Influenza Vaccine Market

The global withdrawal of B/Yamagata lineage is altering the restructuring of the trivalent inactivated influenza vaccine market. Many governments have strengthened the procurement of seasonal doses and boosted their domestic production. Combined with the latest market analysis by Lucintel, policy and production intensification continue to be the drivers of market activity.

  • United States: The FDA's Vaccines and Related Biological Products Advisory Committee endorsed trivalent formulations for 2025-2026 and removed B/Yamagata in March. The CDC recommended vaccination for individuals 6 months and older. This decision should simplify the projected production for the next three to five years.
  • China: Public health procurement in accordance with the recommendations of the Chinese National Immunization Program, 2025-2026 seasonal influenza vaccination guidelines were maintained and domestic producers of trivalent vaccines, Sinovac and Hualan Biological, continued their production. In 2025, specific recommendations for older adults were also retained. This policy provides sustained demand for both domestic production and recurrent orders.
  • Germany: Germany's STIKO recommended seasonal influenza vaccination for individuals 60 years and older, pregnant women, and individuals of high risk in 2025. This was also the EU recommendation to all member states. The EU's transition to trivalent formulations for seasonal influenza vaccines was also maintained.
  • India: As with the previous year, manufacturing of vaccines for India's Universal Immunization Program happened in the Public sector. However, Serum Institute of India (SII) and Zydus Lifesciences produced seasonal influenza vaccines. India has a growing vaccine manufacturing capacity and Local vaccine markets that will help accelerate incremental production of trivalent vaccines.
  • Japan: Japanese Ministry of Health, Labor and Welfare (MHLW) made no changes to their seasonal influenza recommendations for the 2025 - 2026 season, so domestic manufacturers prepared trivalent vaccines based on B Yamagata Lineage. Routine vaccination for older adults in Japan ensures a stable customer base and sustains Local vaccine manufacturing.

Features of the Global Trivalent Inactivated Influenza Vaccine Market

  • Market Size Estimates: trivalent inactivated influenza vaccine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: trivalent inactivated influenza vaccine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: trivalent inactivated influenza vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the trivalent inactivated influenza vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the trivalent inactivated influenza vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the trivalent inactivated influenza vaccine market by type (nasal spray, intramuscular injection, and intradermal injection), application (hospital, clinic, public health agency, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Trivalent Inactivated Influenza Vaccine Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Nasal Spray: Trends and Forecast (2019-2035)
  • 4.4 Intramuscular Injection: Trends and Forecast (2019-2035)
  • 4.5 Intradermal Injection: Trends and Forecast (2019-2035)

5. Global Trivalent Inactivated Influenza Vaccine Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospital: Trends and Forecast (2019-2035)
  • 5.4 Clinic: Trends and Forecast (2019-2035)
  • 5.5 Public Health Agency: Trends and Forecast (2019-2035)
  • 5.6 Others: Trends and Forecast (2019-2035)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Trivalent Inactivated Influenza Vaccine Market by Region

7. North American Trivalent Inactivated Influenza Vaccine Market

  • 7.1 Overview
  • 7.2 North American Trivalent Inactivated Influenza Vaccine Market by Type
  • 7.3 North American Trivalent Inactivated Influenza Vaccine Market by Application
  • 7.4 United States Trivalent Inactivated Influenza Vaccine Market
  • 7.5 Mexican Trivalent Inactivated Influenza Vaccine Market
  • 7.6 Canadian Trivalent Inactivated Influenza Vaccine Market

8. European Trivalent Inactivated Influenza Vaccine Market

  • 8.1 Overview
  • 8.2 European Trivalent Inactivated Influenza Vaccine Market by Type
  • 8.3 European Trivalent Inactivated Influenza Vaccine Market by Application
  • 8.4 German Trivalent Inactivated Influenza Vaccine Market
  • 8.5 French Trivalent Inactivated Influenza Vaccine Market
  • 8.6 Spanish Trivalent Inactivated Influenza Vaccine Market
  • 8.7 Italian Trivalent Inactivated Influenza Vaccine Market
  • 8.8 United Kingdom Trivalent Inactivated Influenza Vaccine Market

9. APAC Trivalent Inactivated Influenza Vaccine Market

  • 9.1 Overview
  • 9.2 APAC Trivalent Inactivated Influenza Vaccine Market by Type
  • 9.3 APAC Trivalent Inactivated Influenza Vaccine Market by Application
  • 9.4 Japanese Trivalent Inactivated Influenza Vaccine Market
  • 9.5 Indian Trivalent Inactivated Influenza Vaccine Market
  • 9.6 Chinese Trivalent Inactivated Influenza Vaccine Market
  • 9.7 South Korean Trivalent Inactivated Influenza Vaccine Market
  • 9.8 Indonesian Trivalent Inactivated Influenza Vaccine Market

10. ROW Trivalent Inactivated Influenza Vaccine Market

  • 10.1 Overview
  • 10.2 ROW Trivalent Inactivated Influenza Vaccine Market by Type
  • 10.3 ROW Trivalent Inactivated Influenza Vaccine Market by Application
  • 10.4 Middle Eastern Trivalent Inactivated Influenza Vaccine Market
  • 10.5 South American Trivalent Inactivated Influenza Vaccine Market
  • 10.6 African Trivalent Inactivated Influenza Vaccine Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Trivalent Inactivated Influenza Vaccine Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 AstraZeneca
    • Company Overview
    • Trivalent Inactivated Influenza Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Sanofi S.A
    • Company Overview
    • Trivalent Inactivated Influenza Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Abbott
    • Company Overview
    • Trivalent Inactivated Influenza Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 GlaxoSmithKline
    • Company Overview
    • Trivalent Inactivated Influenza Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Merck
    • Company Overview
    • Trivalent Inactivated Influenza Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Novartis
    • Company Overview
    • Trivalent Inactivated Influenza Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Pfizer
    • Company Overview
    • Trivalent Inactivated Influenza Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Trivalent Inactivated Influenza Vaccine Market
  • Figure 2.1: Usage of Trivalent Inactivated Influenza Vaccine Market
  • Figure 2.2: Classification of the Global Trivalent Inactivated Influenza Vaccine Market
  • Figure 2.3: Supply Chain of the Global Trivalent Inactivated Influenza Vaccine Market
  • Figure 3.1: Driver and Challenges of the Trivalent Inactivated Influenza Vaccine Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Trivalent Inactivated Influenza Vaccine Market by Type in 2019, 2026, and 2035
  • Figure 4.2: Trends of the Global Trivalent Inactivated Influenza Vaccine Market ($B) by Type
  • Figure 4.3: Forecast for the Global Trivalent Inactivated Influenza Vaccine Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Nasal Spray in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Intramuscular Injection in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Figure 4.6: Trends and Forecast for Intradermal Injection in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Figure 5.1: Global Trivalent Inactivated Influenza Vaccine Market by Application in 2019, 2026, and 2035
  • Figure 5.2: Trends of the Global Trivalent Inactivated Influenza Vaccine Market ($B) by Application
  • Figure 5.3: Forecast for the Global Trivalent Inactivated Influenza Vaccine Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospital in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Clinic in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Public Health Agency in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Figure 5.7: Trends and Forecast for Others in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Figure 6.1: Trends of the Global Trivalent Inactivated Influenza Vaccine Market ($B) by Region (2019-2026)
  • Figure 6.2: Forecast for the Global Trivalent Inactivated Influenza Vaccine Market ($B) by Region (2027-2035)
  • Figure 7.1: North American Trivalent Inactivated Influenza Vaccine Market by Type in 2019, 2026, and 2035
  • Figure 7.2: Trends of the North American Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2019-2026)
  • Figure 7.3: Forecast for the North American Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2027-2035)
  • Figure 7.4: North American Trivalent Inactivated Influenza Vaccine Market by Application in 2019, 2026, and 2035
  • Figure 7.5: Trends of the North American Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2019-2026)
  • Figure 7.6: Forecast for the North American Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2027-2035)
  • Figure 7.7: Trends and Forecast for the United States Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 7.8: Trends and Forecast for the Mexican Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 7.9: Trends and Forecast for the Canadian Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 8.1: European Trivalent Inactivated Influenza Vaccine Market by Type in 2019, 2026, and 2035
  • Figure 8.2: Trends of the European Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2019-2026)
  • Figure 8.3: Forecast for the European Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2027-2035)
  • Figure 8.4: European Trivalent Inactivated Influenza Vaccine Market by Application in 2019, 2026, and 2035
  • Figure 8.5: Trends of the European Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2019-2026)
  • Figure 8.6: Forecast for the European Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2027-2035)
  • Figure 8.7: Trends and Forecast for the German Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 8.8: Trends and Forecast for the French Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 8.9: Trends and Forecast for the Spanish Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 8.10: Trends and Forecast for the Italian Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 8.11: Trends and Forecast for the United Kingdom Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 9.1: APAC Trivalent Inactivated Influenza Vaccine Market by Type in 2019, 2026, and 2035
  • Figure 9.2: Trends of the APAC Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2019-2026)
  • Figure 9.3: Forecast for the APAC Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2027-2035)
  • Figure 9.4: APAC Trivalent Inactivated Influenza Vaccine Market by Application in 2019, 2026, and 2035
  • Figure 9.5: Trends of the APAC Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2019-2026)
  • Figure 9.6: Forecast for the APAC Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2027-2035)
  • Figure 9.7: Trends and Forecast for the Japanese Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 9.8: Trends and Forecast for the Indian Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 9.9: Trends and Forecast for the Chinese Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 9.10: Trends and Forecast for the South Korean Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 9.11: Trends and Forecast for the Indonesian Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 10.1: ROW Trivalent Inactivated Influenza Vaccine Market by Type in 2019, 2026, and 2035
  • Figure 10.2: Trends of the ROW Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2019-2026)
  • Figure 10.3: Forecast for the ROW Trivalent Inactivated Influenza Vaccine Market ($B) by Type (2027-2035)
  • Figure 10.4: ROW Trivalent Inactivated Influenza Vaccine Market by Application in 2019, 2026, and 2035
  • Figure 10.5: Trends of the ROW Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2019-2026)
  • Figure 10.6: Forecast for the ROW Trivalent Inactivated Influenza Vaccine Market ($B) by Application (2027-2035)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 10.8: Trends and Forecast for the South American Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 10.9: Trends and Forecast for the African Trivalent Inactivated Influenza Vaccine Market ($B) (2019-2035)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Trivalent Inactivated Influenza Vaccine Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Trivalent Inactivated Influenza Vaccine Market (2026)
  • Figure 12.1: Growth Opportunities for the Global Trivalent Inactivated Influenza Vaccine Market by Type
  • Figure 12.2: Growth Opportunities for the Global Trivalent Inactivated Influenza Vaccine Market by Application
  • Figure 12.3: Growth Opportunities for the Global Trivalent Inactivated Influenza Vaccine Market by Region
  • Figure 12.4: Emerging Trends in the Global Trivalent Inactivated Influenza Vaccine Market

List of Tables

  • Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Trivalent Inactivated Influenza Vaccine Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Trivalent Inactivated Influenza Vaccine Market by Region
  • Table 1.3: Global Trivalent Inactivated Influenza Vaccine Market Parameters and Attributes
  • Table 3.1: Trends of the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 3.2: Forecast for the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 4.1: Attractiveness Analysis for the Global Trivalent Inactivated Influenza Vaccine Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 4.4: Trends of Nasal Spray in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 4.5: Forecast for Nasal Spray in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 4.6: Trends of Intramuscular Injection in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 4.7: Forecast for Intramuscular Injection in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 4.8: Trends of Intradermal Injection in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 4.9: Forecast for Intradermal Injection in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 5.1: Attractiveness Analysis for the Global Trivalent Inactivated Influenza Vaccine Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 5.4: Trends of Hospital in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 5.5: Forecast for Hospital in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 5.6: Trends of Clinic in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 5.7: Forecast for Clinic in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 5.8: Trends of Public Health Agency in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 5.9: Forecast for Public Health Agency in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 5.10: Trends of Others in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 5.11: Forecast for Others in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 7.1: Trends of the North American Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 7.2: Forecast for the North American Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 7.7: Trends and Forecast for the United States Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 7.8: Trends and Forecast for the Mexican Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 7.9: Trends and Forecast for the Canadian Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 8.1: Trends of the European Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 8.2: Forecast for the European Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 8.3: Market Size and CAGR of Various Type in the European Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 8.4: Market Size and CAGR of Various Type in the European Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 8.5: Market Size and CAGR of Various Application in the European Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 8.6: Market Size and CAGR of Various Application in the European Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 8.7: Trends and Forecast for the German Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 8.8: Trends and Forecast for the French Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 8.9: Trends and Forecast for the Spanish Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 8.10: Trends and Forecast for the Italian Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 8.11: Trends and Forecast for the United Kingdom Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 9.1: Trends of the APAC Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 9.2: Forecast for the APAC Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 9.7: Trends and Forecast for the Japanese Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 9.8: Trends and Forecast for the Indian Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 9.9: Trends and Forecast for the Chinese Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 9.10: Trends and Forecast for the South Korean Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 9.11: Trends and Forecast for the Indonesian Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 10.1: Trends of the ROW Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 10.2: Forecast for the ROW Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Trivalent Inactivated Influenza Vaccine Market (2019-2026)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Trivalent Inactivated Influenza Vaccine Market (2027-2035)
  • Table 10.7: Trends and Forecast for the Middle Eastern Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 10.8: Trends and Forecast for the South American Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 10.9: Trends and Forecast for the African Trivalent Inactivated Influenza Vaccine Market (2019-2035)
  • Table 11.1: Product Mapping of Trivalent Inactivated Influenza Vaccine Suppliers Based on Segments
  • Table 11.2: Operational Integration of Trivalent Inactivated Influenza Vaccine Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Trivalent Inactivated Influenza Vaccine Revenue
  • Table 12.1: New Product Launches by Major Trivalent Inactivated Influenza Vaccine Producers (2019-2026)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Trivalent Inactivated Influenza Vaccine Market
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!